Tonix Pharmaceuticals Holding Corp Cash Flow Conversion Efficiency
Tonix Pharmaceuticals Holding Corp cash flow conversion efficiency. Based on the latest financial reports, Tonix Pharmaceuticals Holding Corp (TNXP) has a cash flow conversion efficiency ratio of -0.162x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-39.65 Million) by net assets ($245.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Tonix Pharmaceuticals Holding Corp (2008–2025)
Cash flow conversion efficiency of Tonix Pharmaceuticals Holding Corp from 2008 to 2025. This chart illustrates how Tonix Pharmaceuticals Holding Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View TNXP share price today for real-time trading data and today's change.
Tonix Pharmaceuticals Holding Corp Cash Flow Conversion Ratio Explained
Tonix Pharmaceuticals Holding Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Tonix Pharmaceuticals Holding Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tonix Pharmaceuticals Holding Corp ranked by their cash flow conversion efficiency. Also see Tonix Pharmaceuticals Holding Corp market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eureka Acquisition Corp Unit
NASDAQ:EURKU
|
-0.006x |
|
Aemulus Holdings Bhd
KLSE:0181
|
-0.202x |
|
China Harmony Auto Holding Limited
F:HA5
|
0.043x |
|
Talga Group Ltd
F:TGX
|
-0.234x |
|
Song Shang Electronics Co Ltd
TWO:6156
|
-0.075x |
|
Wilmar Cahaya Indonesia Tbk
JK:CEKA
|
-0.075x |
|
Melrose Industries PLC
LSE:MRO
|
0.003x |
|
Hunya Foods Co Ltd
TW:1236
|
0.013x |
Annual Cash Flow Conversion Efficiency for Tonix Pharmaceuticals Holding Corp (2008–2025)
The table below shows the annual cash flow conversion efficiency of Tonix Pharmaceuticals Holding Corp from 2008 to 2025. Review how financially flexible is Tonix Pharmaceuticals Holding Corp to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $245.15 Million | $-99.84 Million | -0.407x | +6.71% |
| 2024-12-31 | $139.56 Million | $-60.92 Million | -0.437x | +54.84% |
| 2023-12-31 | $105.53 Million | $-102.00 Million | -0.967x | -104.24% |
| 2022-12-31 | $207.18 Million | $-98.05 Million | -0.473x | -37.00% |
| 2021-12-31 | $218.72 Million | $-75.56 Million | -0.345x | +37.65% |
| 2020-12-31 | $87.65 Million | $-48.57 Million | -0.554x | +80.44% |
| 2019-12-31 | $9.42 Million | $-26.68 Million | -2.833x | -179.72% |
| 2018-12-31 | $23.66 Million | $-23.97 Million | -1.013x | -30.36% |
| 2017-12-31 | $24.62 Million | $-19.13 Million | -0.777x | +47.19% |
| 2016-12-31 | $25.36 Million | $-37.31 Million | -1.471x | -39.30% |
| 2015-12-31 | $40.26 Million | $-42.53 Million | -1.056x | -66.91% |
| 2014-12-31 | $36.09 Million | $-22.84 Million | -0.633x | +51.61% |
| 2013-12-31 | $6.51 Million | $-8.52 Million | -1.308x | +78.05% |
| 2012-12-31 | $958.71K | $-5.71 Million | -5.959x | -654.41% |
| 2011-12-31 | $-2.45 Million | $-2.64 Million | 1.075x | -66.04% |
| 2010-12-31 | $-5.68K | $-17.98K | 3.165x | +236.78% |
| 2009-12-31 | $12.04K | $-27.87K | -2.314x | -321.32% |
| 2008-12-31 | $42.91K | $-23.57K | -0.549x | -- |
About Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and T… Read more